JP2024527974A5 - - Google Patents

Info

Publication number
JP2024527974A5
JP2024527974A5 JP2024504984A JP2024504984A JP2024527974A5 JP 2024527974 A5 JP2024527974 A5 JP 2024527974A5 JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024527974 A5 JP2024527974 A5 JP 2024527974A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/110539 external-priority patent/WO2023011631A1/zh
Publication of JP2024527974A publication Critical patent/JP2024527974A/ja
Publication of JP2024527974A5 publication Critical patent/JP2024527974A5/ja
Pending legal-status Critical Current

Links

JP2024504984A 2021-08-05 2022-08-05 小細胞肺がんを治療する薬物の組み合わせ Pending JP2024527974A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110897167.2 2021-08-05
CN202110897167 2021-08-05
PCT/CN2022/110539 WO2023011631A1 (zh) 2021-08-05 2022-08-05 治疗小细胞肺癌的药物组合

Publications (2)

Publication Number Publication Date
JP2024527974A JP2024527974A (ja) 2024-07-26
JP2024527974A5 true JP2024527974A5 (https=) 2025-08-13

Family

ID=85154833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504984A Pending JP2024527974A (ja) 2021-08-05 2022-08-05 小細胞肺がんを治療する薬物の組み合わせ

Country Status (8)

Country Link
US (1) US20240343807A1 (https=)
EP (1) EP4382123A4 (https=)
JP (1) JP2024527974A (https=)
KR (1) KR20240046526A (https=)
CN (1) CN116209443A (https=)
AU (1) AU2022321783A1 (https=)
CA (1) CA3227992A1 (https=)
WO (1) WO2023011631A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7582952B2 (ja) * 2019-01-25 2024-11-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 腫瘍治療用の併用医薬組成物
WO2024155790A2 (en) * 2023-01-18 2024-07-25 Onkosxcel Therapeutics, Llc Novel approach for treatment of cancer using immunomodulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
JP7455806B2 (ja) * 2018-07-18 2024-03-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド キノリン誘導体と抗体による薬物の組み合わせ
CN117085017A (zh) * 2018-09-18 2023-11-21 正大天晴药业集团股份有限公司 用于治疗小细胞肺癌的喹啉衍生物
CN111617243B (zh) * 2019-02-28 2023-12-19 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
CN113518621A (zh) * 2019-03-07 2021-10-19 南京爱德程医药科技有限公司 按顺序使用卡奎替尼(安罗替尼)和标准化学疗法或免疫疗法的组合以治疗癌症
CA3133141A1 (en) * 2019-03-15 2020-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating small cell lung cancer
US20220193066A1 (en) * 2019-05-20 2022-06-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for combination treatment of small cell lung cancer
CN118267469A (zh) * 2019-06-10 2024-07-02 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
JP7799638B2 (ja) * 2020-06-30 2026-01-21 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 腫瘍を治療するための薬物

Similar Documents

Publication Publication Date Title
Levy et al. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
CN102753176B (zh) 含有cdc7抑制剂和抗癌药的治疗组合物
RU2013126630A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2013520442A5 (https=)
JP2013542241A5 (https=)
JP2012509889A5 (https=)
JP2008503476A5 (https=)
JP2020508317A5 (https=)
RU2017133273A (ru) Ингибиторы pd-1 / pd-l1 для лечения рака
RU2011125518A (ru) Антиангиогенная терапия, применяемая для лечения рака молочной железы
JP2011522773A5 (https=)
HRP20160045T1 (hr) Metoda lijeäśenja raka pomoä†u antagonista dll4 i kemoterapijskog sredstva
JP2024527974A5 (https=)
JP2021510725A5 (https=)
JP2011520921A5 (https=)
EA018447B1 (ru) Применение комбинации 7-(2,5-дигидро-4-имидазо[1,2-а]пиридин-3-ил-2,5-диоксо-1н-пиррол-3-ил)-9-фтор-1,2,3,4-тетрагидро-2-(1-пиперидинилкарбонил)пирроло[3,2,1-jk][1,4]бензодиазепина с химиотерапевтическим агентом для лечения злокачественных опухолей
JP2022512851A5 (https=)
Sprangers et al. 16 Conventional Chemotherapy
JP2024533067A5 (https=)
JP2007277240A5 (https=)
JPWO2022270524A5 (https=)
CN115461079A (zh) 用于治疗肾癌的联用药物
Tanaka et al. Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro
JP2023531090A5 (https=)